Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Yi-Chen Yao"'
Autor:
Shu‐Qiang Yuan, Run‐Cong Nie, You‐Sheng Huang, Ying‐Bo Chen, Si‐Yu Wang, Xiao‐Wei Sun, Yuan‐Fang Li, Ze‐Kun Liu, Yan‐Xing Chen, Yi‐Chen Yao, Yu Xu, Hai‐Bo Qiu, Yao Liang, Wei Wang, Ze‐Xian Liu, Qi Zhao, Rui‐Hua Xu, Zhi‐Wei Zhou, Feng Wang
Publikováno v:
Cancer Communications, Vol 43, Iss 12, Pp 1312-1325 (2023)
Abstract Background Circulating tumor DNA (ctDNA) is a promising biomarker for predicting relapse in multiple solid cancers. However, the predictive value of ctDNA for disease recurrence remains indefinite in locoregional gastric cancer (GC). Here, w
Externí odkaz:
https://doaj.org/article/68c843f124474fe0aa17402518065e35
Autor:
Qi Zhao, Feng Wang, Yan-Xing Chen, Shifu Chen, Yi-Chen Yao, Zhao-Lei Zeng, Teng-Jia Jiang, Ying-Nan Wang, Chen-Yi Wu, Ying Jing, You-Sheng Huang, Jing Zhang, Zi-Xian Wang, Ming-Ming He, Heng-Ying Pu, Zong-Jiong Mai, Qi-Nian Wu, Renwen Long, Xiaoni Zhang, Tanxiao Huang, Mingyan Xu, Miao-Zheng Qiu, Hui-Yan Luo, Yu-Hong Li, Dong-Shen Zhang, Wei-Hua Jia, Gong Chen, Pei-Rong Ding, Li-Ren Li, Zheng-Hai Lu, Zhi-Zhong Pan, Rui-Hua Xu
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
The ChangKang (Heathy Bowel) project was established to collect molecular and clinical information of a thousand Chinese colorectal cancer patients. Here, the authors present the genomic landscape of the ChangKang cohort and find a subgroup of patien
Externí odkaz:
https://doaj.org/article/ee0548bf4a574cba8d5b0964a7e38b91
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-10 (2022)
Highlights Increased use of primary tumor resection plus metastasectomy benefited patients with left-sided tumors but not those with right-sided tumors. Increased use of primary tumor resection alone did not improve survival in either left or right-s
Externí odkaz:
https://doaj.org/article/2efe81e64b194403a8d4064924ff2cbb
Autor:
Zi-Xian Wang, Yi-Chen Yao, Zong-Jiong Mai, Wu-Hao Lin, You-Sheng Huang, Ying Jin, Hui-Yan Luo, Dong-Sheng Zhang, Feng-Hua Wang, Feng Wang, Gong Chen, Pei-Rong Ding, Yun-Fei Yuan, Yu-Hong Li, Jin-Hua Huang, Zhi-Zhong Pan, Rui-Hua Xu
Publikováno v:
Engineering, Vol 7, Iss 4, Pp 526-533 (2021)
There is a lack of high-quality, large-scale, real-world evidence from patients with metastatic colorectal cancer (mCRC), especially in China. It remains unclear whether efforts to improve the quality of care for mCRC would improve patient survival o
Externí odkaz:
https://doaj.org/article/f732de77c04a45509f100295641df798
Autor:
Feng Wang, Ming-Ming He, Yi-Chen Yao, Xia Zhao, Zhi-Qiang Wang, Ying Jin, Hui-Yan Luo, Ji-Bin Li, Feng-Hua Wang, Miao-Zhen Qiu, Zhi-Da Lv, De-Shen Wang, Yu-Hong Li, Dong-Sheng Zhang, Rui-Hua Xu
Publikováno v:
Cell Reports Medicine, Vol 2, Iss 9, Pp 100383- (2021)
Summary: This is a phase Ib/II study of regorafenib plus toripalimab for colorectal cancer. The objective response rate (ORR) is 15.2% and the disease control rate is 36.4% in evaluable patients with recommended phase II dose (80 mg regorafenib plus
Externí odkaz:
https://doaj.org/article/5c383b21ae974f8da20b3340ecd629c8
Autor:
YI-CHEN YAO, 姚易辰
106
Today, music classrooms are dazzling, but the counter use of paperwork is still used: students registering classes, adjusting classes, and taking time off are quite frequent, almost becoming the most frequently handled work on the counter. T
Today, music classrooms are dazzling, but the counter use of paperwork is still used: students registering classes, adjusting classes, and taking time off are quite frequent, almost becoming the most frequently handled work on the counter. T
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/58g68p
Autor:
Yi-Chen Yao1,2, Ying Jin1,2, Xue-Fen Lei3, Zi-Xian Wang1,2, Dong-Sheng Zhang1,2, Feng-Hua Wang1,2, Yu-Hong Li1,2, Rui-Hua Xu1,2, Feng Wang1,2 wangfeng@sysucc.org.cn
Publikováno v:
Journal of Cancer. 2022, Vol. 13 Issue 9, p2912-2921. 10p.
Autor:
Hao-Xiang Wu, Yi-Qian Pan, Ye He, Zi-Xian Wang, Wen-Long Guan, Yan-Xing Chen, Yi-Chen Yao, Ning-Yi Shao, Rui-Hua Xu, Feng Wang
Publikováno v:
Journal of Clinical Oncology. 41:1735-1746
PURPOSE Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)–expressing esophageal squamous cell carcinoma (ESCC) by the European Medicines Agency, whereas the US Food a
Autor:
Rui-Hua Xu, Yu-Hong Li, Feng-Hua Wang, Dong-Sheng Zhang, Hui-Yan Luo, Shuang-Zhen Chen, Si-Mei Shi, Ying Guo, Hong Qiu, Zhi-Qiang Wang, Zong-Jiong Mai, Ying Jin, Xiang-Yuan Wu, Zeng-Qing Guo, Qing-Feng Zou, Ying Yuan, Jie-Er Ying, Fu-Xiang Zhou, Zhi-Xiang Zhuang, Yi-Chen Yao, Zhi-Gang Ma, Xiao-Hua Hu, Wei Wang, Yan Zhang, Wei-Jia Fang, Xiang-Lin Yuan, Yan-Qiao Zhang, Jian Xiao, Ming-Ming He, Feng Wang
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b06772fe70faec5ac401fdfce8e7dbf
https://doi.org/10.1158/1078-0432.22488381.v1
https://doi.org/10.1158/1078-0432.22488381.v1
Autor:
Rui-Hua Xu, Yu-Hong Li, Feng-Hua Wang, Dong-Sheng Zhang, Hui-Yan Luo, Shuang-Zhen Chen, Si-Mei Shi, Ying Guo, Hong Qiu, Zhi-Qiang Wang, Zong-Jiong Mai, Ying Jin, Xiang-Yuan Wu, Zeng-Qing Guo, Qing-Feng Zou, Ying Yuan, Jie-Er Ying, Fu-Xiang Zhou, Zhi-Xiang Zhuang, Yi-Chen Yao, Zhi-Gang Ma, Xiao-Hua Hu, Wei Wang, Yan Zhang, Wei-Jia Fang, Xiang-Lin Yuan, Yan-Qiao Zhang, Jian Xiao, Ming-Ming He, Feng Wang
Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ddb2013da603b76379f8a09fb0d76e8
https://doi.org/10.1158/1078-0432.22488387.v1
https://doi.org/10.1158/1078-0432.22488387.v1